Cancer-Theraputics, Inc - The leader in activated cell technologies
 
 

Investors

 

CANCER CELLULAR THERAPEUTICS, INC.

CODE OF ETHICS FOR SENIOR OFFICERS

Cancer Cellular Therapeutics, Inc. (the “Company”) is committed to conducting its business in compliance with applicable laws and regulations and in accordance with high standards of business conduct. The Company strives to maintain the highest standards of accuracy, completeness and integrity in its financial dealings, records and reports. These standards serve as the basis for managing the Company’s business, for meeting the Company’s duties to its stockholders and for maintaining compliance with financial reporting requirements. Accordingly, the Company has adopted this Code of Ethics for its Chief Executive Officer (CEO) and any other senior officers (collectively, the “Senior Officers”).

I. Honest and Ethical Conduct

  • Senior Officers will exhibit and promote honest and ethical conduct by:
  • Encouraging and rewarding professional integrity and eliminating barriers to responsible behavior.
  • Promoting the ethical handling of actual or apparent conflicts of interest between personal and professional relationships.
  • Respecting the confidentiality of information acquired in the course of work, except when authorized or otherwise legally obligated to disclose such information.
  • Periodically communicating these ethical standards throughout the organization.

II. Financial Records and Periodic Reports

Senior Officers will establish and manage the enterprise transaction and reporting systems and procedures to provide that:

  • Business transactions are properly authorized and accurately and timely recorded on the Company’s books and records in accordance with U.S. generally accepted accounting principles (GAAP) and policies established by the Company.
  • False or artificial statements are not made in the Company’s books and records, financial statements and related communications.
  • The retention or proper disposal of Company records shall be in accordance with applicable legal and regulatory requirements and any records retention policies established by the Company.

III. Compliance with Applicable Laws, Rules and Regulations

Senior Officers will establish mechanisms to:

  • Educate Company employees about applicable governmental laws, rules and regulations.
  • Monitor compliance with applicable governmental laws, rules and regulations.

IV. Reporting of Non-Compliance

Senior Officers will promptly bring to the attention of the Audit Committee of the CEO:

  • Material information that calls into question disclosures made by the Company in its public communications.
  •  Information concerning significant deficiencies or material weaknesses in the design or operation of the Company’s “internal control over financial reporting” or other factors that could adversely affect the Company’s ability to record, process, summarize and report financial data.
  • Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s financial reporting, disclosures or internal control over financial reporting.
  • Information concerning a violation of this Code or any other Company conduct codes, including any actual or apparent conflicts of interest between personal and professional relationships, involving management or other employees who have a significant role in the Company’s financial reporting, disclosures or internal control over financial reporting.
  • Evidence of a material violation by the Company or its employees or agents of applicable governmental laws, rules or regulations.

V. Disciplinary Action

In the event of a violation by a Senior Officer of this Code, the CEO and Board of Directors shall be responsible for recommending appropriate disciplinary and/or remedial actions.

Contact

Individuals interested in investing in CCTI should contact Dr. Oldham at 1-800-279-2796 or rko.1@earthlink.net.




 


Cancer Cellular Therapeutics, Inc. (CCTI) is a leader in activated cell technology offering cell cryopreservation (CryoBank) services, Tumor Derived Activated Cells (TDAC) and Autologous Tumor Cell Vaccines.